Coverage of a new PCSK9 trial makes bold claims about prevention and risk reduction. But how well do they hold up to scrutiny ...

In late March 2026, the FDA warned of severe liver injuries, including vanishing bile duct syndrome, linked to ...

U.S. President Donald Trump secured agreements with 16 major pharmaceutical companies to bring U.S. prescription drug prices ...

Amgen Inc. (NASDAQ:AMGN) is one of the best pharma stocks to invest in now. Amgen Inc. (NASDAQ:AMGN) announced on March 28 ...

Europe needs to rethink drug pricing to stay competitive, ​lobby group says (Adds comment from European Commission in paragraphs 18-19) LONDON/PARIS, March 31 (Reuters) - Drugmakers are delaying ...

Trump says the industry has been unfair to US consumers and has sought to tie the cost for Americans to what is paid ...

Bristol Myers Squibb is adding three prescription medications on TrumpRx.gov on Monday, offering discounts of up to 90%, FOX ...

Repatha is the Only PCSK9 Inhibitor to Significantly Reduce the Risk of First CV Events in High-Risk Primary Prevention VESALIUS-CV Subgroup Findings Reinforce Benefit ...

Investigators suggest LDL targets typically reserved for secondary prevention are best in high-risk patients with diabetes.

Evolocumab (Repatha) reduced risk of a first major cardiovascular (CV) event in patients with diabetes but no known atherosclerosis in a substudy of the VESALIUS-CV trial. The PCSK9 inhibitor cut ...

Repatha is the Only PCSK9 Inhibitor to Significantly Reduce the Risk of First CV Events in High-Risk Primary Prevention ...

The platform now features a total of 54 discounted prescription medications available from six participating companies.